To calculate the greenhouse gas production potential for an individual, we summed the emissions potential of all foods consumed by that person, expressed as kilograms of CO 2 produced per day per person (kgCO 2 -eq/person-day) 28
Where DSIP fits and where it does not Because the evidence is weak, the appropriate role for DSIP in any clinical conversation is narrow
Whether they work, or are safe, remains to be seen
It is known that the CV protection effect of GLP-1RAs have been proven through eight large-scale clinical studies, including Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) [66], LEADER [44], Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)-6 [67], Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [68], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [69], Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [70], Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 [67,71], and AMPLITUDE-O [51]
